To avoid daratumumab-mediated fratricide, the CD38-gene can be deleted in expanded primary NK cells without affecting their in vivo persistence or the ADCC activity against MM cell lines and primary MM cells [26]. This evidence concerns the gene CD38 and Miyoshi myopathy.